STOCK TITAN

[Form 4] Fulgent Genetics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Fulgent Genetics (FLGT) — Form 4 insider transaction: the company’s CFO and Treasurer reported a tax-related share withholding tied to equity vesting. On 10/26/2025, 2,743 shares of common stock were withheld under transaction code F at a price of $23.74 to satisfy tax obligations upon the vesting of restricted stock units assumed in the November 7, 2022 merger agreement.

Following this administrative transaction, the reporting person beneficially owned 334,118 shares directly. This filing reflects routine tax withholding associated with stock-based compensation rather than an open-market purchase or sale.

Fulgent Genetics (FLGT) — Transazione interna ai sensi del modulo 4: il CFO e Tesoriere della società ha riferito una trattenuta azionaria legata a motivi fiscali al vesting dell'equity. Il 26/10/2025, sono state trattenute 2.743 azioni ordinarie sotto il codice di transazione F a un prezzo di 23,74 dollari per soddisfare gli obblighi fiscali al vesting delle unità azionarie soggette a vincolo assunte nell'accordo di fusione del 7 novembre 2022.

Dopo questa operazione amministrativa, la persona che segnala deteneva beneficiariamente 334.118 azioni direttamente. Questa dichiarazione riflette una trattenuta fiscale di routine associata alla compensazione basata su azioni, piuttosto che un acquisto o vendita sul mercato aperto.

Fulgent Genetics (FLGT) — Transacción de insider de Formulario 4: el CFO y Tesorero de la empresa reportaron una retención de acciones relacionada con impuestos vinculada al vesting de la equidad. El 26/10/2025, se retuvieron 2,743 acciones comunes bajo el código de transacción F a un precio de 23,74 dólares para satisfacer obligaciones fiscales al vesting de las unidades de acciones restringidas asumidas en el acuerdo de fusión del 7 de noviembre de 2022.

Tras esta operación administrativa, la persona que reporta poseía de forma beneficiosa 334,118 acciones directamente. Esta presentación refleja una retención fiscal de rutina asociada a la compensación basada en acciones, no una compra o venta en el mercado abierto.

퓨걸런트 제네틱스(FLGT) — Form 4 내부자 거래: 회사의 최고재무책임자(CFO) 겸 재무담당이 주식 보유세 의무를 충당하기 위해 주식 양도장부를 보유한 사례를 보고했습니다. 2025년 10월 26일, 보조거래 코드 F로 주당 23.74달러의 가격에 2,743주 보통주가 보유되었으며, 2022년 11월 7일의 합병 계약에서 인수된 제한주식유닛(RSU) vesting에 따른 세금 의무를 충당하기 위함입니다.

이 행정적 거래 이후, 보고자는 직접 334,118주를 보유하게 되었습니다. 이 신고는 주식 기반 보상과 관련된 일반적인 세금 원천징수를 반영하는 것이며, 공개시장 매매가 아님을 나타냅니다.

Fulgent Genetics (FLGT) — Form 4 opération d'initié: le directeur financier et trésorier de l'entreprise a signalé une retenue d'actions liée à l'impôt associée à la vesting des actions. Le 26/10/2025, 2 743 actions ordinaires ont été retenues sous le code de transaction F à un prix de 23,74 dollars pour satisfaire les obligations fiscales lors de la vesting des unités d'actions restreintes assumées dans l'accord de fusion du 7 novembre 2022.

Suite à cette transaction administrative, la personne déclarant détenait bénéficiairement 334 118 actions directement. Cette déclaration reflète une retenue d'impôt de routine associée à la rémunération basée sur les actions plutôt qu'un achat ou une vente sur le marché libre.

Fulgent Genetics (FLGT) — Form 4 Insidertransaktion: Der CFO und Schatzmeister des Unternehmens meldete eine steuerlich bedingte Aktienabgabe in Zusammenhang mit der Vesting von Eigenkapital. Am 26.10.2025 wurden 2.743 Stammaktien unter dem Transaktionscode F zu einem Preis von 23,74 USD einbehalten, um steuerliche Verpflichtungen bei der Vesting der angenommenen Restricted Stock Units (RSU) aus dem Fusionsvertrag vom 7. November 2022 zu erfüllen.

Nach dieser administrativen Transaktion hielt die meldende Person vorteilhaft 334.118 Aktien direkt. Diese Einreichung spiegelt routinemäßige Quellensteuerabzüge im Zusammenhang mit aktienbasierter Vergütung wider und nicht einen Kauf oder Verkauf am offenen Markt.

فولجنت جينيتكس (FLGT) — استناد Form 4 لمعاملة داخلية: أفاد المدير المالي وأمين الخزانة للشركة عن حجز أسهم متعلق بالضريبة مربوط بتقصير الأسهم عند الاستحقاق. في 26/10/2025، تم حجز 2,743 سهمًا من الأسهم العادية بموجب رمز المعاملة F وبسعر 23.74 دولارًا لتلبية الالتزامات الضريبية عند استحقاق وحدات الأسهم المقيدة المفترضة في اتفاق الاندماج المؤرخ في 7 نوفمبر 2022.

بعد هذه الصفقة الإدارية، أصبح الشخص المبلغ له يمتلك فعلياً 334,118 سهمًا مباشرة. تعكس هذه النشرة حجزًا ضريبيًا روتينيًا مرتبطًا بالتعويض القائم على الأسهم وليس شراء أو بيع في السوق المفتوحة.

Positive
  • None.
Negative
  • None.

Fulgent Genetics (FLGT) — Transazione interna ai sensi del modulo 4: il CFO e Tesoriere della società ha riferito una trattenuta azionaria legata a motivi fiscali al vesting dell'equity. Il 26/10/2025, sono state trattenute 2.743 azioni ordinarie sotto il codice di transazione F a un prezzo di 23,74 dollari per soddisfare gli obblighi fiscali al vesting delle unità azionarie soggette a vincolo assunte nell'accordo di fusione del 7 novembre 2022.

Dopo questa operazione amministrativa, la persona che segnala deteneva beneficiariamente 334.118 azioni direttamente. Questa dichiarazione riflette una trattenuta fiscale di routine associata alla compensazione basata su azioni, piuttosto che un acquisto o vendita sul mercato aperto.

Fulgent Genetics (FLGT) — Transacción de insider de Formulario 4: el CFO y Tesorero de la empresa reportaron una retención de acciones relacionada con impuestos vinculada al vesting de la equidad. El 26/10/2025, se retuvieron 2,743 acciones comunes bajo el código de transacción F a un precio de 23,74 dólares para satisfacer obligaciones fiscales al vesting de las unidades de acciones restringidas asumidas en el acuerdo de fusión del 7 de noviembre de 2022.

Tras esta operación administrativa, la persona que reporta poseía de forma beneficiosa 334,118 acciones directamente. Esta presentación refleja una retención fiscal de rutina asociada a la compensación basada en acciones, no una compra o venta en el mercado abierto.

퓨걸런트 제네틱스(FLGT) — Form 4 내부자 거래: 회사의 최고재무책임자(CFO) 겸 재무담당이 주식 보유세 의무를 충당하기 위해 주식 양도장부를 보유한 사례를 보고했습니다. 2025년 10월 26일, 보조거래 코드 F로 주당 23.74달러의 가격에 2,743주 보통주가 보유되었으며, 2022년 11월 7일의 합병 계약에서 인수된 제한주식유닛(RSU) vesting에 따른 세금 의무를 충당하기 위함입니다.

이 행정적 거래 이후, 보고자는 직접 334,118주를 보유하게 되었습니다. 이 신고는 주식 기반 보상과 관련된 일반적인 세금 원천징수를 반영하는 것이며, 공개시장 매매가 아님을 나타냅니다.

Fulgent Genetics (FLGT) — Form 4 opération d'initié: le directeur financier et trésorier de l'entreprise a signalé une retenue d'actions liée à l'impôt associée à la vesting des actions. Le 26/10/2025, 2 743 actions ordinaires ont été retenues sous le code de transaction F à un prix de 23,74 dollars pour satisfaire les obligations fiscales lors de la vesting des unités d'actions restreintes assumées dans l'accord de fusion du 7 novembre 2022.

Suite à cette transaction administrative, la personne déclarant détenait bénéficiairement 334 118 actions directement. Cette déclaration reflète une retenue d'impôt de routine associée à la rémunération basée sur les actions plutôt qu'un achat ou une vente sur le marché libre.

Fulgent Genetics (FLGT) — Form 4 Insidertransaktion: Der CFO und Schatzmeister des Unternehmens meldete eine steuerlich bedingte Aktienabgabe in Zusammenhang mit der Vesting von Eigenkapital. Am 26.10.2025 wurden 2.743 Stammaktien unter dem Transaktionscode F zu einem Preis von 23,74 USD einbehalten, um steuerliche Verpflichtungen bei der Vesting der angenommenen Restricted Stock Units (RSU) aus dem Fusionsvertrag vom 7. November 2022 zu erfüllen.

Nach dieser administrativen Transaktion hielt die meldende Person vorteilhaft 334.118 Aktien direkt. Diese Einreichung spiegelt routinemäßige Quellensteuerabzüge im Zusammenhang mit aktienbasierter Vergütung wider und nicht einen Kauf oder Verkauf am offenen Markt.

فولجنت جينيتكس (FLGT) — استناد Form 4 لمعاملة داخلية: أفاد المدير المالي وأمين الخزانة للشركة عن حجز أسهم متعلق بالضريبة مربوط بتقصير الأسهم عند الاستحقاق. في 26/10/2025، تم حجز 2,743 سهمًا من الأسهم العادية بموجب رمز المعاملة F وبسعر 23.74 دولارًا لتلبية الالتزامات الضريبية عند استحقاق وحدات الأسهم المقيدة المفترضة في اتفاق الاندماج المؤرخ في 7 نوفمبر 2022.

بعد هذه الصفقة الإدارية، أصبح الشخص المبلغ له يمتلك فعلياً 334,118 سهمًا مباشرة. تعكس هذه النشرة حجزًا ضريبيًا روتينيًا مرتبطًا بالتعويض القائم على الأسهم وليس شراء أو بيع في السوق المفتوحة.

Fulgent Genetics (FLGT) — Form 4 内部人士交易: 公司的首席财务官兼司库报告了与股票归属相关的税务扣留。于 2025-10-26,按照交易代码 F,扣留了 2,743 股普通股,价格为 23.74 美元,以在已在 2022 年 11 月 7 日的并购协议中假定的受限股票单位(RSU)归属时履行税务义务。

在此行政交易之后,披露人直接受益拥有 334,118 股股票。此份申报反映的是与基于股票的薪酬相关的常规税款扣留,而非在公开市场的买卖。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kim Paul

(Last) (First) (Middle)
C/O FULGENT GENETICS, INC.
4399 SANTA ANITA AVENUE

(Street)
EL MONTE CA 91731

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO and Treasurer
3. Date of Earliest Transaction (Month/Day/Year)
10/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/26/2025 F 2,743(1) D $23.74 334,118 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.
/s/ Paul Kim 10/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did FLGT disclose in this Form 4?

A routine tax withholding: 2,743 common shares were withheld on 10/26/2025 at $23.74 upon RSU vesting.

Who is the reporting person in FLGT’s Form 4?

The company’s CFO and Treasurer filed the report as a single reporting person.

How many FLGT shares does the insider own after the transaction?

Beneficial ownership is 334,118 shares, held directly, after the reported transaction.

What does transaction code F signify in the Form 4?

Code F indicates shares were withheld by the issuer to cover taxes due at vesting of equity awards.

What triggered the tax withholding event for FLGT?

The vesting of restricted stock units assumed under the November 7, 2022 merger agreement.
Fulgent Genetics

NASDAQ:FLGT

FLGT Rankings

FLGT Latest News

FLGT Latest SEC Filings

FLGT Stock Data

713.50M
20.46M
33.16%
53.92%
6.71%
Diagnostics & Research
Services-medical Laboratories
Link
United States
EL MONTE